Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.
Choose a source to read (2)
Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.
1 additional source qualifications - review before use
The severe nondialysis reduction retains the indication-specific schedule. The intermittent-HD statement is a separate population, not a general ESRD instruction.
Before applying: Keep the continuous or intermittent cycle attached to its indication; do not extrapolate the HD statement to PD or CRRT.
Also check: PEMAZYRE: amount and cycle are separate decisions
Official source
PEMAZYRE - official severe-renal schedule check
Product / population
PEMAZYRE - official severe-renal schedule check; selected renal passages, not a complete prescribing monograph.
Identity check: DailyMed labeler Incyte Corporation. Current archive version 17 published 2026-06-15. This archive date is separate from the prescribing-information revision and does not itself prove that renal instructions changed. Raw SPL XML was not independently downloaded or hashed.
Renal dosing, restrictions and evidence limits
At MDRD eGFR 15-29 mL/min/1.73 m2, the official dose is 9 mg using the schedule for the indication. Cholangiocarcinoma uses once-daily treatment for 14 days followed by 7 days off; myeloid/lymphoid neoplasms with FGFR1 rearrangement use continuous once-daily dosing. A renal dose reduction changes the amount, not this distinction between cycles. Interaction and toxicity modifications remain separate.
Source revision: Prescribing information revised June 2023. | Retrieved: 2026-09-09. Retrieval date is not the revision date.
All sources, comparison tools and evidence navigation
Source-first renal review
Evidence sources and renal implications
Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.
Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.
Find:
Enter at least two characters. Searches stay on this page and are not saved or sent.
All source summaries, original wording and provenance
Before applying a renal protocol
Check the setting. Compare whole sources.
No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.
Share a reproducible source review
Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.
Select two distinct source versions. The complete stored summaries will appear below.
Source-by-source comparison
These protocols may disagree and may apply to different settings. This view does not reconcile or endorse a patient-specific regimen.
Build a source-review outline for documentation
This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.
Choose one or two sources above or use the source checkboxes below.
Renal-context checklist: population, kidney trend and dialysis
These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.
Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.
These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.
dose table scope
PEMAZYRE: amount and cycle are separate decisions
The severe nondialysis reduction retains the indication-specific schedule. The intermittent-HD statement is a separate population, not a general ESRD instruction.
How to use this: Keep the continuous or intermittent cycle attached to its indication; do not extrapolate the HD statement to PD or CRRT.
Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.
New source summary - independent clinical review pending. Summaries of the identified label sections are included locally. Source import and numeric transcription checks are not independent two-reference validation. Do not treat this card as an approved institutional dosing protocol.
Official source
PEMAZYRE - official severe-renal schedule check
PEMAZYRE - official severe-renal schedule check; selected renal passages, not a complete prescribing monograph.
No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.
Compare or copy source versions
All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.
Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
DailyMed / Incyte Corporation · PEMAZYRE - official severe-renal schedule check; selected renal passages, not a complete prescribing monograph.
Renal method: eGFR, mL/min/1.73 m2; retain body-surface-area indexing. MDRD. Source date: Prescribing information revised June 2023. Retrieved: 2026-09-09
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.
Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.
Renal dosing, restrictions and evidence limits
At MDRD eGFR 15-29 mL/min/1.73 m2, the official dose is 9 mg using the schedule for the indication. Cholangiocarcinoma uses once-daily treatment for 14 days followed by 7 days off; myeloid/lymphoid neoplasms with FGFR1 rearrangement use continuous once-daily dosing. A renal dose reduction changes the amount, not this distinction between cycles. Interaction and toxicity modifications remain separate.
RDM50-official-pemigatinib-pemazyre-a926552a51-C1 · Source locator: Sections 2.2 and 2.5, lines 341-345 and 396-398.
Source-specific limits
Identity check: DailyMed labeler Incyte Corporation. Current archive version 17 published 2026-06-15. This archive date is separate from the prescribing-information revision and does not itself prove that renal instructions changed. Raw SPL XML was not independently downloaded or hashed.
GlobalRPh-hosted RX List · Pemigatinib - PEMAZYRE tablets; selected renal passages, not a complete prescribing monograph.
Renal method: eGFR, mL/min/1.73 m2; retain body-surface-area indexing. Equation: MDRD. Source date: Source revision date not established in selected retrieval. Retrieved: 2026-09-09
Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.
Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.
Renal dosing, restrictions and evidence limits
At MDRD eGFR 15-29 mL/min/1.73 m2, reduce PEMAZYRE to 9 mg while retaining the indication-specific intermittent or continuous schedule. Mild/moderate impairment (30-89) needs no adjustment. The source also explicitly recommends no renal adjustment in ESRD below 15 when receiving intermittent hemodialysis. That dialysis statement is distinct from the severe nondialysis recommendation; do not apply it to peritoneal dialysis, CRRT or nondialysis ESRD without supporting evidence.
Additional summaries stored on this page: 1 official-label, 1 RX List, 0 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.
This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.